For HER2-positive advanced gastric cancer in upfront settings, a combination of pembrolizumab with trastuzumab plus chemotherapy showed promising efficacy, and other combinations of anti-HER2 therapy and immune checkpoint inhibitors have indicated promising effects. This evidence concerns the gene ERBB2 and gastric cancer.